百时美施贵宝Bristol Myers Squibb Co. (BMY) 2008年年度报告「NYSE」.pdf

1、5asdBioPharma:our Strategy in action2008 annual reporton left:Zhen Jin,a research scientist at KAI Pharmaceuticals in South San Francisco,compares tissue samples as part of a cardio-vascular disease collaboration with Bristol-Myers Squibb.The lead compound from this collaboration is a novel investig

2、ational medica-tion for the emergency room treatment of acute heart attack.This compound is in Phase IIb clinical development and has been granted Fast Track status by the U.S.Food and Drug Administration because of its potential to treat life-threatening disease and to address an unmet medical need

3、.As a next-generation BioPharma leader,Bristol-Myers Squibb is committed to helping patients prevail against serious disease.To do so,we are complementing and enhancing our internal capabilities with a suite of innovative alliances,partnerships and acquisitions.We call this our String of Pearls stra

4、tegy.The collaboration with KAI is part of that strategy,which includes seven major transactions completed to date since August 2007.on the front cover:A Bristol-Myers Squibb scientist in Wallingford,Connecticut,examines a 1,536-well plate for screening drug candidates against disease targets.Each w

5、ell contains about one-millionth of a liter of a particular compound.Thats barely enough to see.Yet its plenty for advanced high-speed robotic technol-ogy to use this plate and 800 others to screen more than a million compounds at a time.In one of the tiny wells on this plate,perhaps,is the next bre

6、akthrough medication for cancer,HIV/AIDS,cardiovas-cular disease,Alzheimers or other serious illness.Its just part of what being BioPharma is all about.In a year when global economic upheaval and continuing industry challenges threw many companies off track,we kept our sights trained on the vision w